Masimo (MASI) Scheduled to Post Earnings on Tuesday

Masimo (NASDAQ:MASI) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.71 per share for the quarter. Persons interested in registering for the company’s conference call can do so using this link.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.43. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The firm had revenue of $548.90 million for the quarter, compared to the consensus estimate of $545.69 million. During the same period in the previous year, the firm posted $1.32 earnings per share. The firm’s revenue was down 11.0% on a year-over-year basis. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Masimo Stock Up 0.6 %

MASI stock opened at $137.00 on Friday. The company has a 50 day moving average of $136.10 and a two-hundred day moving average of $118.52. The company has a market cap of $7.25 billion, a price-to-earnings ratio of 90.73 and a beta of 0.99. Masimo has a 12-month low of $75.22 and a 12-month high of $188.76. The company has a quick ratio of 1.22, a current ratio of 2.18 and a debt-to-equity ratio of 0.64.

Analysts Set New Price Targets

A number of analysts recently issued reports on MASI shares. StockNews.com raised Masimo from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. BTIG Research lifted their price target on Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a report on Monday, March 25th. Piper Sandler increased their price objective on Masimo from $70.00 to $117.00 and gave the stock a “neutral” rating in a report on Monday, February 26th. Wells Fargo & Company upgraded shares of Masimo from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $117.00 to $160.00 in a research note on Monday, March 25th. Finally, Stifel Nicolaus upgraded shares of Masimo from a “hold” rating to a “buy” rating and increased their price target for the stock from $148.00 to $170.00 in a research note on Monday, April 15th. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Masimo currently has an average rating of “Hold” and an average price target of $137.43.

Insider Activity

In related news, Director Craig B. Reynolds sold 40,000 shares of the firm’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $136.17, for a total value of $5,446,800.00. Following the transaction, the director now directly owns 7,406 shares in the company, valued at approximately $1,008,475.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.70% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.